Celecoxib for the treatment of non muscle invasive bladder cancer. Results from the first phase II clinical trial

被引：1
|
作者：
Pagliarulo, V. [1 ]
Martines, I. [1 ]
Telari, S. [1 ]
Ancona, P. [1 ]
Trerotoli, P. [2 ]
Albo, G. [1 ]
Pagliarulo, A. [1 ]
机构：
[1] Univ Bari, Sezione Urol, DETO, I-70121 Bari, Italy
[2] Univ Bari, Dipartimento Med Interna & Med Publ, I-70121 Bari, Italy
来源：
EUROPEAN UROLOGY SUPPLEMENTS | 2008年 / 7卷 / 03期
关键词：
D O I：
10.1016/S1569-9056(08)60909-4
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
912
引用
收藏
页码：299 / 299
页数：1
相关论文
共 50 条
  • [31] Preliminary results of first-in-human cryotherapy for non-muscle invasive bladder cancer
    Hoffman, A.
    Nativ, O.
    Malshy, K.
    Sadeh, O.
    Mullerad, M.
    Kochavi, E.
    Amiel, G. E.
    EUROPEAN UROLOGY, 2023, 83
  • [32] Organ preservation strategies in bladder cancer and the results of BC2001 trial, a Phase III trial of chemoradiotherapy in muscle invasive bladder cancer
    Hussain, Syed A.
    James, Nicholas D.
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2009, 24 : S82 - S82
  • [33] Precise diagnosis and treatment of non-muscle invasive bladder cancer - A clinical perspective
    Yang, Yongjun
    Wang, Chen
    Li, Zonglin
    Lu, Qiang
    Li, Yuanwei
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [34] Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group
    Kamat, Ashish M.
    Sylvester, Richard J.
    Bohle, Andreas
    Palou, Joan
    Lamm, Donald L.
    Brausi, Maurizio
    Soloway, Mark
    Persad, Raj
    Buckley, Roger
    Colombel, Marc
    Witjes, J. Alfred
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (16) : 1935 - +
  • [35] Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer
    Zahoor, Haris
    Mir, Maria C.
    Barata, Pedro C.
    Stephenson, Andrew J.
    Campbell, Steven C.
    Fergany, Amr
    Dreicer, Robert
    Garcia, Jorge A.
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (06) : 1231 - 1238
  • [36] Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer
    Haris Zahoor
    Maria C. Mir
    Pedro C. Barata
    Andrew J. Stephenson
    Steven C. Campbell
    Amr Fergany
    Robert Dreicer
    Jorge A. Garcia
    Investigational New Drugs, 2019, 37 : 1231 - 1238
  • [37] Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: Analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502)
    Weickhardt, A. J.
    Foroudi, F.
    Xie, J.
    Kanojia, K.
    Sidhom, M.
    Pal, A.
    Grimison, P.
    Zhang, A.
    Ng, S.
    Tang, C.
    Hovey, E.
    Chen, C.
    Hruby, G.
    Guminski, A.
    Mcjannett, M.
    Conduit, C. J.
    Lawrentschuk, N.
    Tran, B.
    Davis, I. D.
    Hayne, D.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1332 - S1332
  • [38] THE ROLE OF FLEXIBLE BLUE LIGHT CYSTOSCOPY IN SURVEILLANCE OF NON-MUSCLE INVASIVE BLADDER CANCER. RESULTS FROM A NORDIC REGISTRY
    Zieger, Karsten Egbert Arnold
    Young-Halvorsen, Kristine
    Malmstrom, Per-Uno
    JOURNAL OF UROLOGY, 2023, 209 : E100 - E100
  • [39] S1605: Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer
    Singh, Parminder
    Catherine, Tangen
    Lerner, Seth P.
    McConkey, David
    Plets, Melissa
    Lucia, M. Scott
    Woods, Michael
    Bivalacqua, Trinity
    Kassouf, Wassim
    Bangs, Richard Carlton
    Thompson, Ian Murchie
    Black, Peter C.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [40] Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study
    Shi, Hongzhe
    Zhang, Wen
    Bi, Xingang
    Wang, Dong
    Xiao, Zejun
    Guan, Youyan
    Guan, Kaopeng
    Tian, Jun
    Bai, Hongsong
    Hu, Linjun
    Cao, Chuanzhen
    Jiang, Weixing
    Hu, Zhilong
    Zhang, Jin
    Chen, Yan
    Zheng, Shan
    Feng, Xiaoli
    Li, Changling
    Li, Yexiong
    Ma, Jianhui
    Liu, Yueping
    Zhou, Aiping
    Shou, Jianzhong
    CANCER RESEARCH AND TREATMENT, 2021, 53 (04): : 1156 - 1165
12345